Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tissue Penetration of Zerbaxa in Diabetic Patients With Lower Limb Infections
NCT02620774Phase 1Completed
- Sponsor
- Hartford Hospital
- Start
- Feb 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ceftolozane + tazobactam in Wound infection (WI) (2 arms), sponsored by Hartford Hospital. Primary endpoints: Ceftolozane Tissue Penetration and Tazobactam Tissue Penetration. Started Feb 2016; status: completed.
02
Drugs
ceftolozane + tazobactam
03
Conditions
Wound infection (WI)
Beyond the preview
Go deeper on NCT02620774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02620774.